.png)
.png)
.png)
If you have recognised that you or a family member has a problem with amphetamines — speed, crystal meth, Yaba, or prescription stimulants misused — the natural next question is: what does stopping actually involve, and why does it require professional medical support? A common and dangerous belief delays treatment: that because amphetamine withdrawal does not produce the dramatic physical seizures of alcohol or heroin withdrawal, it can be managed at home through determination. This belief costs recovery time and causes preventable harm.
The truth is that amphetamine withdrawal — particularly from methamphetamine — is clinically severe, carries real psychiatric and cardiovascular risks, and has one of the highest unaided relapse rates of any substance. And methamphetamine introduces a dimension that most other drugs do not: direct neurotoxic damage to the dopamine-producing neurons of the brain, which means that every week of delayed treatment allows further structural brain damage to accumulate. The case for medical treatment is not precautionary — it is neurological.
This guide is written for families and individuals who have made the decision that something must change and want to understand what professional treatment actually involves — from the first call through detox, therapy, and the months of recovery that follow. At Jeevan Sankalp's amphetamine de-addiction programme in Dehradun, every stage of treatment is matched to the specific neurological demands of stimulant recovery.
What Amphetamine Withdrawal Actually Involves: The Neurochemistry
Amphetamine withdrawal is not a simple detox — it is a period of profound neurological readjustment that is more complex and longer-lasting for methamphetamine than for almost any other commonly used substance. Understanding what the brain is going through explains the symptoms and makes sense of why professional management is necessary.
Amphetamines flood the brain with dopamine and norepinephrine — often 5× above normal for methamphetamine. The brain adapts by reducing receptor sensitivity and natural neurotransmitter production. When amphetamines are removed, both dopamine and norepinephrine drop sharply below normal — often to less than 40% of baseline. The result is the crash: profound depression, exhaustion, anhedonia, and an inability to feel any positive emotion. The person is not simply "back to normal" — they are in a state of deep neurochemical deficit, worse than before they ever used amphetamines.
The immediate period after stopping is the crash. The exhausted nervous system shuts down: the person sleeps for 15–20 hours per day, sometimes longer. When they wake, they feel profoundly depressed, emotionally flat, irritable, and intensely craving amphetamines. Appetite returns strongly — often the first robust appetite they have had in months, as the appetite suppression of active use is removed. For methamphetamine, the crash is more severe and longer than for powder amphetamines, lasting up to 4–7 days. This is the period of highest psychiatric risk — suicidal ideation is documented in severe cases and requires clinical monitoring.
After the crash, acute withdrawal continues. Sleep reverses — hypersomnia gives way to insomnia as the nervous system continues recalibrating. Anhedonia persists: the person is awake but unable to feel pleasure from anything. Cognitive fog, poor memory, and slowed processing are prominent — particularly in methamphetamine users whose dopamine neurons have been directly damaged. Craving remains intense and is triggered easily by environmental cues. This is the period when most unaided attempts fail — the contrast between the flatness of sobriety and the remembered intensity of amphetamine use is at its starkest, with no obvious improvement in sight.
Unlike cocaine — which causes primarily functional changes to the dopamine system — methamphetamine is directly toxic to dopamine-producing neurons. It destroys the terminals of dopamine neurons in the prefrontal cortex and striatum, reducing the brain's long-term capacity to produce natural dopamine. During withdrawal, the brain must not only readjust neurochemically but also begin the process of neurological repair. This is why methamphetamine withdrawal is more severe and longer-lasting, and why the cognitive impairments of meth withdrawal — memory problems, slowed thinking, difficulty making decisions — can take 12–24 months to resolve rather than the 6–12 months typical of cocaine.
Protracted Abstinence Withdrawal Syndrome (PAWS) follows the acute phase and is particularly severe and prolonged with methamphetamine. For 12–24 months after stopping, unpredictable waves of intense craving, anhedonia, depression, cognitive fog, emotional dysregulation, and sleep disturbance can emerge — sometimes after weeks of feeling relatively stable. These PAWS episodes are neurological recovery in progress, not treatment failure. Understanding this and having clinical support during PAWS is what distinguishes people who achieve sustained recovery from those who relapse believing that recovery is not possible for them.
For methamphetamine users who developed psychosis during active use, stopping does not immediately resolve the psychiatric state. Amphetamine-induced psychosis — paranoia, hallucinations, severe agitation — can persist for days to weeks after stopping, and in some heavy long-term users may continue for months. During the withdrawal period, without antipsychotic management in a clinical setting, psychosis can be dangerous and frightening for the person and those around them. Psychiatric stabilisation is therefore a specific priority in methamphetamine withdrawal management that requires clinical expertise.
The Amphetamine Withdrawal Timeline: What to Expect at Each Stage
Knowing the timeline removes the fear of the unknown and provides a framework for what the clinical team is managing at each stage. For methamphetamine, the timeline is longer than for most other substances — families and patients should plan for this from the outset.
| Phase | Key Symptoms | Craving Level | Clinical Risk | What Treatment Provides |
|---|---|---|---|---|
| Hours
12–24 The onset |
Extreme fatigue rapidly setting in; depression beginning; irritability; anxiety; craving intensifying as the drug clears the system | Severe | Suicidal ideation in severe cases; cardiovascular instability; immediate relapse risk; unresolved psychosis may escalate | Safe environment; clinical assessment; medical monitoring; immediate psychiatric evaluation if psychosis present; sleep and nutritional support initiated |
| Days
1–7 The crash |
Profound depression; hypersomnia (15–20+ hours sleep daily); strong appetite returning; emotional flatness; on waking — intense craving and despair; psychosis may persist (meth); cardiovascular readjustment | Very High | Psychiatric risk highest; cardiovascular monitoring required; decision-making neurologically impaired; relapse risk near-total without structured care | Round-the-clock monitoring; antipsychotic management where indicated; antidepressant initiation; sleep support; nutritional rehabilitation; removal of access to amphetamines |
| Weeks
2–4 Acute withdrawal |
Insomnia replaces hypersomnia; persistent anhedonia; cognitive fog and memory difficulties; anxiety; mood instability; craving triggered by cues; psychosis gradually resolving (if present) with treatment | High | Anhedonia drives relapse — nothing else feels good; prefrontal cortex still significantly impaired; insomnia elevates risk | CBT introduced; group therapy; trigger mapping; psychoeducation about PAWS; sleep management; motivational interviewing; psychiatric review |
| Months
1–3 PAWS begins |
Unpredictable PAWS waves — intense craving, depression, emotional dysregulation without obvious trigger; some good days between difficult periods; cognitive improvement beginning; natural pleasure beginning to return briefly | Moderate–High (variable) | PAWS waves can overwhelm without clinical support; "good week" overconfidence is itself a relapse risk; cognitive impairment still significant in meth users | Weekly aftercare; PAWS monitoring; CBT skill reinforcement; family check-ins; cognitive recovery tracking |
| Months
3–6 Consolidation |
Craving frequency reducing; natural pleasure returning more consistently; mood more stable; prefrontal cortex function measurably improving; PAWS waves less frequent; energy levels normalising | Reducing | Overconfidence risk; stopping aftercare prematurely; alcohol lowering inhibition; major stressors triggering PAWS | Fortnightly aftercare; social reintegration; family relationship rebuilding; vocational planning |
| Months
6–12 Sustained recovery |
Dopamine system largely recovered; cognitive function significantly improved; genuine natural pleasure; cravings rare and manageable; mood stable; PAWS episodes uncommon | Low | Conditioned triggers still present; major life stress can activate late cravings; meth users may still experience occasional PAWS episodes | Monthly aftercare; peer community; continued relapse prevention |
| Months 12–24 Meth extended recovery |
Specific to methamphetamine — continued neurological repair; cognitive function approaching pre-use levels in most patients; PAWS episodes rare; life fully sustainable without the drug | Very Low | Conditioned memories remain but manageable; the risk of late relapse if aftercare is discontinued before month 24 | Quarterly aftercare for meth patients through month 24; annual review; ongoing relapse prevention maintenance |
6 Reasons Why Amphetamine Withdrawal Still Requires Medical Treatment
"No dangerous physical seizures" does not mean "no clinical risk" — and it does not mean "manageable at home." These six reasons explain specifically why professional medical treatment is not optional for amphetamine dependency:
When You Call Jeevan Sankalp: What the Clinical Assessment Covers
The first step for every patient is a thorough clinical assessment — completed before admission to ensure that the treatment approach, programme length, and medication protocol are correctly matched to the individual's situation. This assessment is free, confidential, and takes approximately 45–60 minutes.
Type of amphetamine (speed, crystal meth, Yaba, prescription stimulants); duration of use; pattern (binge, daily, continuous); route of administration (oral, smoked, snorted, injected); current quantity; prior treatment attempts and what triggered relapse each time. This history directly determines the recommended programme length — crystal meth and Yaba typically require 60 or 90 days; speed dependency may be appropriate for 28 days depending on severity.
For methamphetamine and Yaba users, psychiatric evaluation is the first clinical priority — not an afterthought. Screening for active psychosis (paranoid delusions, hallucinations, agitation), the severity of depression, and suicidal ideation. History of pre-existing psychiatric conditions. Any family psychiatric history. The psychiatric findings determine immediate medication needs and the clinical approach to the first week of withdrawal.
ECG to assess heart rhythm; blood pressure measurement; clinical history of chest pain, palpitations, or cardiac symptoms during use. Amphetamines cause significant cardiovascular damage over time — hypertension, cardiac muscle damage, arrhythmias. Cardiovascular monitoring during the first week of withdrawal is clinically indicated for heavy or long-term users.
Brief cognitive assessment covering memory, processing speed, and executive function — documenting the baseline from which recovery is measured and identifying the level of neurotoxic impairment that will shape the pace of the therapeutic programme. Nutritional blood tests assess vitamin B deficiencies, zinc, iron, and general metabolic health — malnutrition is near-universal in methamphetamine dependency and must be addressed as a clinical priority from Day 1.
Home environment safety for recovery. Family relationships — who understands what is happening and who can provide genuine support versus who constitutes a trigger risk. Employment and financial situation. Legal circumstances if relevant. Social network and peer group — does the person's existing social circle involve others who use? This shapes the aftercare plan significantly, particularly for methamphetamine where environmental triggers are powerful and persistent.
Prior treatment episodes — what programme, what duration, what happened. What triggered relapse: was it PAWS, a specific trigger situation, the home environment, insufficient aftercare? Prior relapse history is not a disqualifying factor — it is the most valuable clinical data available. Understanding specifically what was unaddressed in previous treatment directly shapes the design of this episode to be more effective.
The First Week of Treatment: What to Expect, Day by Day
For most families and patients, the first week is the most feared — the unknown of what withdrawal will actually feel like. Here is what that week looks like at Jeevan Sankalp, where every day has a specific clinical purpose:
Intake and documentation. Medical examination: ECG, blood pressure, blood tests, physical health review. Psychiatric assessment — for methamphetamine patients, psychosis screening is immediate. Medication protocol established based on findings: antipsychotics initiated if psychosis is present; antidepressants commenced; sleep medication provided. Accommodation shown; daily schedule and programme explained. A family orientation session — what the programme involves, what is and is not helpful during the first week, how to interpret what they will see. If the person is coming in during or after a binge, the crash begins during or shortly after admission. Medical staff are present continuously.
The crash is at its deepest on Days 2–4 for most patients — sleeping for very long periods, waking to intense depression and craving, then sleeping again. Medical staff monitor cardiovascular status and psychiatric symptoms continuously. For methamphetamine patients with persisting psychosis, antipsychotic medication is titrated and its effect monitored. Light, nutritious food is provided and encouraged — appetite often returns strongly at this stage as the stimulant appetite suppression lifts. Therapeutic engagement is minimal and intentionally so — the brain is not in a state where CBT can be productively absorbed. The clinical priority is safety, comfort, psychiatric stability, and medical stabilisation. Patients and families are told in advance that Days 2–4 will be the most difficult — this predictability reduces the terror of experiencing it.
By Day 5–6, most patients are spending more waking time and beginning to engage with their environment. Psychosis — where present — is typically substantially reduced by this point with antipsychotic treatment. Depression persists and anhedonia remains significant, but there is often a small but perceptible shift upward from the Day 3–4 low. The first individual counselling session typically begins here — not with intensive CBT but with supportive psychoeducation: what is happening in the brain, what PAWS is and what to expect, and why the flatness and craving are neurological, temporary, and characteristically timed. This preparation is itself clinically protective — knowing that what you are experiencing has a name, a mechanism, and a predictable trajectory makes it significantly more survivable.
A visible shift for most patients by the end of Week 1: more alert, more able to engage with peers and staff, sleep improving incrementally, appetite functioning. The first full day of therapeutic programme participation — group session in the morning, individual session in the afternoon. Sleep is still disrupted for most patients and will remain so for several more weeks. A formal clinical review is held: medical status, medication response, psychiatric stability, and the week-ahead clinical plan. For the family, a brief Day 7 update call or visit confirms progress and prepares them for what weeks 2–4 will look like.
Medications Used in Amphetamine De-Addiction Treatment
Unlike heroin or alcohol treatment, there is currently no approved pharmacological substitute for amphetamines — no equivalent of methadone or buprenorphine. However, medications play a critically important supportive role, particularly for methamphetamine, where the psychiatric and neurological complexity of withdrawal is greater than for most other substances.
| Medication Category | Purpose in Treatment | When Used |
|---|---|---|
|
Antipsychotics (e.g., olanzapine, quetiapine, risperidone) |
Manage amphetamine-induced psychosis — paranoia, hallucinations, and severe agitation. Quetiapine additionally supports sleep and reduces anxiety. Antipsychotics are a priority medication for methamphetamine withdrawal where psychosis is present or suspected | Initiated on Day 1 where psychosis is present; titrated over 1–4 weeks; reviewed by consulting psychiatrist; duration depends on psychosis resolution |
|
Antidepressants (e.g., mirtazapine, bupropion, SSRIs) |
Manage severe crash depression and support dopamine system recovery. Mirtazapine additionally supports appetite and sleep. Bupropion has evidence for reducing stimulant craving in some patients. Address the anhedonia that is the primary driver of relapse in amphetamine withdrawal | Initiated in Days 1–3 if crash depression is clinically significant; continued through withdrawal period and reviewed at 4–6 weeks; may be tapered or continued as clinically indicated |
| Sleep
Medications (non-dependent agents preferred) |
Manage the severe sleep dysregulation of amphetamine withdrawal — from hypersomnia in the crash phase to persistent insomnia in acute withdrawal. Sleep deprivation dramatically elevates relapse risk and must be actively managed throughout the programme | From Days 2–14 as clinically indicated; reviewed weekly; non-dependent agents strongly preferred |
|
Anti-Anxiety Medications (short-term, non-dependent) |
Manage acute agitation, anxiety, and psychological distress during the crash and early acute withdrawal phases — particularly in the first 3–7 days when these symptoms can be severe and destabilising | Short-term acute phase use only; carefully selected to avoid creating secondary dependency; not used routinely — only where the clinical picture indicates |
|
Cardiovascular Medications (antihypertensives) |
Manage blood pressure instability during early abstinence in heavy amphetamine users. Amphetamines cause significant cardiovascular damage — hypertension, cardiac muscle changes, arrhythmias — that require clinical management during withdrawal and beyond | As indicated by ECG and blood pressure monitoring from Day 1; cardiology consultation arranged if significant abnormalities found |
| Nutritional Supplementation (B vitamins, thiamine, zinc, multivitamins, protein) |
Address severe nutritional deficiencies universal in amphetamine dependency. B vitamins are essential for dopamine synthesis and neurological repair — their deficiency directly slows cognitive recovery. A structured dietary rehabilitation programme supports neurotoxic repair alongside supplementation | From Day 1 throughout the residential programme; food programme specifically designed to support dopamine neuron recovery; blood tests repeated at weeks 2 and 4 to track nutritional recovery |
The Core Therapies in Amphetamine De-Addiction Treatment
The primary treatment for amphetamine dependency is psychological — medication stabilises the brain for therapy, but therapy is where the work of sustained recovery is done. These five therapeutic approaches form the clinical core of the Jeevan Sankalp programme, each adapted for the specific features of stimulant addiction:
28-Day, 60-Day, and 90-Day Programmes: Which Is Clinically Right?
For amphetamine dependency — especially methamphetamine — programme length is one of the most consequential clinical decisions. The recommendations below are based on clinical evidence and the specific neurological demands of each substance:
| Programme | What It Covers | Best For | 12-Month Abstinence Rate (with aftercare) |
|---|---|---|---|
| 28 Days | Medical detox and stabilisation; introduction to CBT and relapse prevention; group and family therapy; discharge planning with aftercare | Speed (amphetamine sulphate) only — first-time treatment, lower severity, no psychosis, strong home environment. Not typically recommended for crystal meth or Yaba | 35–45% |
| 60 Days | Full detox; psychiatric stabilisation; deeper CBT programme; anhedonia peak managed within treatment; comprehensive trigger mapping; trauma-informed therapy; extended family therapy | Yaba dependency; moderate crystal meth use; prior relapse; co-occurring depression or anxiety; home environment with some risk factors; previous 28-day programme not sufficient | 50–60% |
| 90 Days | Full detox and psychiatric stabilisation; complete neurological recovery window; advanced CBT; full lifestyle restructuring; vocational and cognitive recovery planning; comprehensive family programme; early PAWS management within treatment | Crystal meth (ice/shabu) — strongly preferred. Also: severe or long-standing dependency; Yaba with psychosis; multiple prior relapses; significant co-occurring mental health conditions; high-risk home environment | 65–75% |
Discharge and Aftercare: Supporting Recovery for 12–24 Months
For amphetamine dependency — and methamphetamine in particular — discharge from the residential programme is the beginning of a structured aftercare period, not the end of treatment. The neurological recovery timeline demands ongoing clinical support that matches it.
- Written relapse response plan — specific protocol for what to do if craving becomes physical relapse
- Full aftercare schedule confirmed for 12–24 months
- Family briefing session — PAWS education, what to watch for, how to respond
- Emergency contact — clinical team available outside office hours
- Medication review — any medications continued post-discharge with follow-up
- Cognitive recovery baseline — so progress can be measured at follow-up
- Trigger map reviewed and finalised with patient and family
- Months 1–2: Weekly sessions — craving review, PAWS monitoring, trigger debrief, sleep and mood, family check-in
- Months 3–4: Fortnightly — CBT skill consolidation, social reintegration, cognitive recovery tracking
- Months 5–8: Monthly — sustained recovery maintenance, vocational reintegration, relationship rebuilding
- Months 9–12: Monthly — longer-term planning, annual review at month 12
- Months 13–24 (meth patients): Quarterly check-ins — late PAWS monitoring, continued relapse prevention
- Year 3+: Annual check-in; available as needed
Families Who Made the Decision — and What Treatment Was Actually Like
"We did not know what to expect when our son was admitted for crystal meth. We were told the first four days would be difficult and they were — he slept almost continuously and when he woke he was deeply depressed. But the clinical team had prepared us: they told us that this was the crash and that it was normal and expected, that Day 3 would likely be the worst, and that by Day 6 or 7 we would see a shift. They were exactly right. By Day 7 he was in his first group session. What I was not fully prepared for was how much the family therapy sessions would help us — not just him. Understanding the neurotoxic damage and what PAWS would look like in months 2 and 3 meant that when those difficult waves came, we knew how to respond. He is 15 months clean. The quarterly check-in calls still happen and we all find them valuable."
— Parents of patient, crystal meth dependency (90-day programme), Dehradun — 15 months sobriety
"My brother was admitted with active psychosis from meth use — he had not slept in four days and believed that people were following him. We were terrified. Within 72 hours of admission, the antipsychotic medication had substantially reduced the paranoia — he was sleeping and beginning to recognise that what he had been experiencing was the drug. The team explained that this is methamphetamine psychosis, that it is a medical condition and not madness, and that it resolves with treatment and abstinence in most cases. He completed 90 days. The psychosis did not return after stopping. He is now 11 months clean and working again. The medication, the clinical expertise, and the consistent presence of the treatment team during that terrifying first week made the difference between my brother recovering and something much worse happening at home."
— Sister of patient, crystal meth dependency with psychosis, Mussoorie — 11 months sobriety
"I want to be honest about the first week because I think people need to know what to expect. The crash was real — I slept for most of it and when I was awake I felt more depressed than I have ever felt in my life. But the medical team had told me before I was admitted that Days 3 and 4 would be the worst and that by Day 7 something would shift. Having that map made it bearable. I knew what I was in rather than feeling like this was how recovery felt permanently. The CBT sessions that started in Week 2 showed me something I had never understood — that I was not actually more capable on meth, I was just more certain that I was. That was the turning point. Eight months out of the 60-day programme, my memory is better, my sleep is normal, and I am doing genuinely better work than I ever did on the drug. The monthly aftercare calls keep me honest. I would not be here without the clinical structure."
— Former patient, Yaba/methamphetamine dependency (60-day programme), Dehradun — 8 months sobriety
Frequently Asked Questions
The primary symptoms are: profound depression and anhedonia during the crash (Days 1–7); extreme hypersomnia (15–20 hours sleep daily) giving way to insomnia in weeks 2–4; intense craving, particularly at trigger exposure; cognitive fog, memory difficulties, and slowed thinking (especially in meth users due to neurotoxicity); irritability and anxiety; persistent paranoia or hallucinations in meth users where psychosis was present during use; and suicidal ideation in severe cases during the crash. Methamphetamine withdrawal is more severe and longer-lasting than powder amphetamine or cocaine withdrawal. PAWS can produce waves of craving, depression, and anhedonia for 12–24 months. Medical treatment manages all of these symptoms and provides the environment in which neurological recovery proceeds safely.
Yes — for six critical reasons: (1) unaided relapse rates exceed 80% in the first month; (2) methamphetamine psychosis requires antipsychotic management in a clinical setting; (3) suicidal ideation during crash depression requires psychiatric monitoring; (4) methamphetamine neurotoxicity means the brain is in an actively damaged state — cognitive and impulse control are at their most impaired precisely when they are most needed; (5) medications (antipsychotics, antidepressants, sleep medications) substantially ease withdrawal and reduce relapse risk — but require clinical prescription and monitoring; (6) CBT begins most effectively in the first week, within the structured residential environment. The absence of physical seizures is one of the main reasons meth treatment is delayed — allowing further neurotoxic damage to accumulate.
Amphetamine withdrawal has two phases. The acute phase: crash (Days 1–7) — profound depression, hypersomnia, suicidal ideation risk; acute withdrawal (Weeks 2–4) — insomnia, anhedonia, cognitive fog, intense craving. For methamphetamine, the acute phase is more severe and longer. The extended phase — PAWS — lasts 12–24 months for methamphetamine (longer than the 6–12 months typical for cocaine). During PAWS, unpredictable waves of craving, depression, anhedonia, and cognitive difficulty emerge. These are neurological recovery in progress — not evidence that treatment has failed. Structured aftercare for 12–24 months provides the clinical support that matches this recovery timeline.
There is no approved pharmacological substitute for amphetamines. Medications used for symptom management include: antipsychotics (olanzapine, quetiapine, risperidone) for methamphetamine-induced psychosis and sleep support; antidepressants (mirtazapine, bupropion) for crash depression and appetite; sleep medications for the severe insomnia that follows the crash hypersomnia; anti-anxiety medications for acute agitation; cardiovascular medications for blood pressure abnormalities; and nutritional supplementation (B vitamins, thiamine, zinc, multivitamins) for the malnutrition universal in amphetamine dependency. The primary treatment remains psychological — CBT — supported by these medical interventions. All prescriptions require clinical assessment and monitoring.
Speed (amphetamine sulphate) of lower severity and first-time treatment: 28 days may be appropriate with a strong home environment and no prior relapses. Yaba (meth + caffeine) or moderate crystal meth: 60 days is typically recommended. Crystal methamphetamine (ice/shabu) — particularly with psychosis, long duration of use, multiple prior relapses, or significant cognitive impairment: 90 days is the strong clinical recommendation. The reason for longer programmes with meth is neurological: the neurotoxic damage, the severity and duration of PAWS, and the cognitive impairment during early recovery all mean that 28 days is insufficient for the brain to stabilise enough for durable recovery. The clinical team will recommend the appropriate length based on the individual assessment. 12-month abstinence rates: 28-day (35–45%), 60-day (50–60%), 90-day (65–75%), all with structured aftercare.
Five phases: (1) Admission and clinical assessment — cardiovascular evaluation, psychiatric screening (psychosis first), substance use history, nutritional status, social circumstances; (2) Medical stabilisation — round-the-clock monitoring, antipsychotic management where indicated, antidepressant support, sleep and nutritional rehabilitation; (3) Therapeutic programme — CBT, motivational interviewing, relapse prevention therapy, group therapy, family therapy; (4) Discharge planning — written relapse response plan, aftercare schedule confirmed, family briefing with PAWS education; (5) Extended aftercare — weekly (months 1–2), fortnightly (3–4), monthly through month 12, quarterly through month 24 for meth patients, with family check-ins throughout. Call +91 7078701387 for a free, confidential assessment.
Yes — Jeevan Sankalp accepts both urgent same-day and planned admissions. For urgent situations — active psychosis, suicidal ideation, severe cardiac symptoms, or immediate family safety concerns — call +91 7078701387 immediately. The clinical team will conduct a rapid telephone assessment and guide the fastest safe pathway to admission. Methamphetamine-induced psychosis is a psychiatric emergency and should not be managed at home while awaiting a planned appointment. No referral is required. The clinical team is available every day including weekends. For planned admissions, the assessment and admission date are arranged within 24–48 hours.